# Study of 2 Doses of Oral Live Attenuated Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis

> **NCT00134732** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 150 (—)

## Conditions studied

- Infections, Rotavirus

## Interventions

- **BIOLOGICAL:** Live attenuated human rotavirus vaccine

## Key facts

- **NCT ID:** NCT00134732
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** —
- **Final completion:** 2006-05
- **Target enrollment:** 150 (—)
- **Last updated:** 2016-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00134732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00134732, "Study of 2 Doses of Oral Live Attenuated Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00134732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*